Immune & Antimicrobial
Defensins
Last updated
Dosing on file unverified
Brilacidin (defensin derivative): topical, Phase 2 completed
Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.
Literature on file 3
-
human RCT
NCT02052388: A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) graded on: a randomised study — “Randomized, Double-Blind Study”
Not graded
2 citations whose study design could not be read from the title. Left ungraded rather than guessed at.
- not graded
- not graded
Notes unverified prose
Brilacidin (PMX-30063) Phase 2 (NCT02052388); no native defensin therapeutic; zero human trials for native defensins
Not on file 8
8 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.
- molecular weightnothing we hold supplies it
- molecular formulanothing we hold supplies it
- CAS registry numbernothing we hold supplies it
- PubChem identifiernothing we hold supplies it
- amino-acid sequencenothing we hold supplies it
- SMILES stringnothing we hold supplies it
- InChInothing we hold supplies it
- InChI keynothing we hold supplies it
Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.